{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T11:05:54Z","timestamp":1777806354404,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T00:00:00Z","timestamp":1395446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s12032-014-0930-7","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T09:24:06Z","timestamp":1395393846000},"source":"Crossref","is-referenced-by-count":7,"title":["A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Jing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meilong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengliu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,22]]},"reference":[{"key":"930_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"930_CR2","first-page":"3353","volume":"29","author":"H Woopen","year":"2009","unstructured":"Woopen H, Sehouli J. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res. 2009;29:3353\u20139.","journal-title":"Anticancer Res"},{"key":"930_CR3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273\u201382.","journal-title":"Nat Rev Cancer"},{"key":"930_CR4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2010.07.016","volume":"79","author":"S Barni","year":"2011","unstructured":"Barni S, Cabiddu M, Ghilardi M, Petrelli F. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol. 2011;79:144\u201353.","journal-title":"Crit Rev Oncol Hematol"},{"key":"930_CR5","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1634\/theoncologist.2009-0109","volume":"14","author":"S Kobold","year":"2009","unstructured":"Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist. 2009;14:1242\u201351.","journal-title":"Oncologist"},{"key":"930_CR6","first-page":"5224","volume":"63","author":"D Belotti","year":"2003","unstructured":"Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003;63:5224\u20139.","journal-title":"Cancer Res"},{"key":"930_CR7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2008.04.028","volume":"111","author":"CA Hamilton","year":"2008","unstructured":"Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111:530\u20132.","journal-title":"Gynecol Oncol"},{"key":"930_CR8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","volume":"13","author":"WH Gotlieb","year":"2012","unstructured":"Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13:154\u201362.","journal-title":"Lancet Oncol"},{"key":"930_CR9","first-page":"1899","volume":"4","author":"GJ Beattie","year":"1998","unstructured":"Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res. 1998;4:1899\u2013902.","journal-title":"Clin Cancer Res"},{"key":"930_CR10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2007.06.155","volume":"361","author":"Y Ling","year":"2007","unstructured":"Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR\/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007;361:79\u201384.","journal-title":"Biochem Biophys Res Commun"},{"key":"930_CR11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3181\/0801-RM-7","volume":"233","author":"N Lu","year":"2008","unstructured":"Lu N, Ling Y, Gao Y, Chen Y, Mu R, Qi Q, et al. Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2\/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med (Maywood). 2008;233:1013\u201320.","journal-title":"Exp Biol Med (Maywood)"},{"key":"930_CR12","first-page":"1509","volume":"30","author":"HM Wei","year":"2010","unstructured":"Wei HM, Qin SK, Yin XJ, Chen YL. Therapeutic features of endostar, a modified endostatin, on ascites tumor in mice. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30:1509\u201313.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"930_CR13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343.","journal-title":"N Engl J Med"},{"key":"930_CR14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11033-012-2106-x","volume":"40","author":"L Chang","year":"2013","unstructured":"Chang L, Guo F, Lv Y, Wang Y, Huo B, Wang L, et al. The inhibitory effects of Endostar combined with chemotherapy on human esophageal squamous cell carcinoma xenograft in mice. Mol Biol Rep. 2013;40:669\u201373.","journal-title":"Mol Biol Rep"},{"key":"930_CR15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1477-7819-10-170","volume":"10","author":"B Rong","year":"2012","unstructured":"Rong B, Yang S, Li W, Zhang W, Ming Z. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 2012;10:170.","journal-title":"World J Surg Oncol"},{"key":"930_CR16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1049909111434044","volume":"29","author":"Y Malayev","year":"2012","unstructured":"Malayev Y, Levene R, Gonzalez F. Palliative chemotherapy for malignant ascites secondary to ovarian cancer. Am J Hosp Palliat Care. 2012;29:515\u201321.","journal-title":"Am J Hosp Palliat Care"},{"key":"930_CR17","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010;127:2209\u201321.","journal-title":"Int J Cancer"},{"key":"930_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2013","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18:1\u20139.","journal-title":"Int J Clin Oncol"},{"key":"930_CR19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.canlet.2010.12.004","volume":"301","author":"XQ Li","year":"2011","unstructured":"Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY, Zhen YS. Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth. Cancer Lett. 2011;301:212\u201320.","journal-title":"Cancer Lett"},{"key":"930_CR20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tox.2006.02.007","volume":"222","author":"HM Arafa","year":"2006","unstructured":"Arafa HM, Abdel-Hamid MA, El-Khouly AA, Elmazar MM, Osman AM. Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm. Toxicology. 2006;222:103\u201313.","journal-title":"Toxicology"},{"key":"930_CR21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.4161\/cbt.7.7.6099","volume":"7","author":"JH Egberts","year":"2008","unstructured":"Egberts JH, Schniewind B, Patzold M, Kettler B, Tepel J, Kalthoff H, et al. Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice. Cancer Biol Ther. 2008;7:1044\u201350.","journal-title":"Cancer Biol Ther"},{"key":"930_CR22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1586\/erp.10.45","volume":"10","author":"Y Hao","year":"2010","unstructured":"Hao Y. Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges. Expert Rev Pharmacoecon Outcomes Res. 2010;10:407\u201320.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0930-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-014-0930-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0930-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:31:50Z","timestamp":1559442710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-014-0930-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,22]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["930"],"URL":"https:\/\/doi.org\/10.1007\/s12032-014-0930-7","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,22]]},"article-number":"930"}}